Trial Search Results
18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma
The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").
Stanford is currently accepting patients for this trial.
- Drug: 18-F FTC 146
- Patients with biopsy proven osteosarcoma requiring local surgical intervention.
- ECOG ≤ 2
- Ability to understand and the willingness to sign a written informed consent document.
- Chemotherapy in the past 2 months.
- Prior history of allergic reaction to 18F FTC 146.
- Pregnant or nursing
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study